| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
18,657 |
18,066 |
$1.27M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
22,464 |
21,938 |
$1.02M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
9,826 |
9,553 |
$987K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,311 |
8,123 |
$837K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
7,531 |
7,395 |
$756K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
17,487 |
16,805 |
$696K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
6,072 |
5,933 |
$665K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
6,286 |
6,076 |
$591K |
| 87428 |
|
2,555 |
2,514 |
$169K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
10,663 |
10,443 |
$160K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,972 |
3,551 |
$109K |
| 99429 |
|
6,552 |
3,762 |
$69K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
6,325 |
4,901 |
$68K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,749 |
1,736 |
$59K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,636 |
4,452 |
$44K |
| 99188 |
|
2,486 |
2,387 |
$40K |
| 96127 |
|
7,588 |
7,412 |
$33K |
| 99173 |
|
5,526 |
5,410 |
$17K |
| 92551 |
|
5,394 |
5,225 |
$17K |
| 96161 |
|
4,297 |
4,151 |
$15K |
| 96160 |
|
3,511 |
3,414 |
$11K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
26 |
26 |
$3K |
| 69210 |
|
58 |
52 |
$3K |
| 90651 |
|
1,979 |
1,933 |
$2K |
| 99381 |
|
16 |
15 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
79 |
75 |
$1K |
| 94664 |
|
68 |
68 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
60 |
55 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
17 |
17 |
$862.98 |
| 36416 |
|
1,802 |
1,744 |
$795.92 |
| 36415 |
Collection of venous blood by venipuncture |
1,210 |
1,141 |
$691.35 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,023 |
1,016 |
$605.00 |
| 81002 |
|
148 |
145 |
$456.51 |
| 90670 |
|
5,252 |
5,060 |
$217.24 |
| 83655 |
|
33 |
33 |
$210.15 |
| 94761 |
|
16 |
15 |
$146.08 |
| 90633 |
|
2,937 |
2,834 |
$105.44 |
| 86308 |
|
13 |
13 |
$82.14 |
| 90686 |
|
4,731 |
4,638 |
$62.06 |
| 90715 |
|
344 |
338 |
$32.27 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
31 |
29 |
$1.45 |
| 90723 |
|
4,634 |
4,479 |
$0.00 |
| 90647 |
|
4,564 |
4,408 |
$0.00 |
| 90656 |
|
520 |
511 |
$0.00 |
| 90620 |
|
835 |
822 |
$0.00 |
| 90696 |
|
217 |
208 |
$0.00 |
| 90619 |
|
56 |
55 |
$0.00 |
| 90716 |
|
36 |
36 |
$0.00 |
| 90671 |
|
1,117 |
1,107 |
$0.00 |
| 90734 |
|
1,264 |
1,230 |
$0.00 |
| 90700 |
|
540 |
527 |
$0.00 |
| 90710 |
|
2,046 |
2,007 |
$0.00 |
| 90681 |
|
1,955 |
1,875 |
$0.00 |
| 5250F |
|
241 |
232 |
$0.00 |
| 90707 |
|
37 |
37 |
$0.00 |
| 90685 |
|
30 |
29 |
$0.00 |